Skip to content

To evaluate the Safety and efficacy of Unani formulations in the treatment of Dry Cough

Clinical Validation of Unani Pharmocopoeial Formulation Sharbat Ejaz in Surfa YÄ?bis (Dry Cough)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/02/005526
Enrollment
300
Registered
2015-02-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R05- Cough Health Condition 2: null- Surfa YÄ?bis (Dry Cough)

Interventions

Intervention1: Sharbat Ejaz: Dose :Sharbat Ejaz (Syrup)20 ml BD Orally mixed with 40 ml of Lukewarm water for two weeks Control Intervention1: nil: na

Sponsors

Monetary Support Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either sex in the age group of 18-60 • Surfa YÄ?bis (Dry Cough) of

Exclusion criteria

Exclusion criteria: •Upper Respiratory Tract Infections (URI or URTI) including rhinitis, rhinosinusitis or sinusitis, nasopharyngitis (rhinopharyngitis or common cold), pharyngitis tonsillitis, epiglottitis (supraglottitis), laryngitis, laryngotracheitis, tracheitis, and otitis media. •Lower Respiratory Tract Infections (LRI or LRTI) including pneumonia, lung abscess, and acute bronchitis. •Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema. •Bronchiectasis, pulmonary tuberculosis, pulmonary oedema, interstitial pulmonary fibrosis •Tumours of larynx, bronchi, and lungs •Drug-induced Cough (e.g., ACE Inhibitors) •Diabetes Mellitus, Hypertension •Known cases of severe hepatic, renal or cardiac ailments •H/o addiction (smoking, alcohol, drugs) •Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptomsTimepoint: 2 weeks

Secondary

MeasureTime frame
Hematological and biochemical assessments for safetyTimepoint: 2 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026